Pfizer’s $43B Pursuit Of Seagen: Q&A With Séverine Piot-Deval
Healthcare expert Severine Piot-Deval discusses the Pfizer-Seagan deal with Global Finance magazine.
Healthcare expert Severine Piot-Deval discusses the Pfizer-Seagan deal with Global Finance magazine.
A slow process of switching from physical to digital trade documentation appears to be speeding up.
Private equity firms are attempting to navigate a barren M&A landscape, with trillions in capital ready to deploy. But where?
EY's plan to separate its auditing and consulting businesses from one another to address conflict of interest concerns comes to naught.